Canada RNA Therapeutics Market by Molecule Type, Therapeutic Area, Administration Route, End User, and Province, Forecast to 2035 | 13.4% CAGR to Unlock a USD 3.56 Billion Market
Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Canada RNA Therapeutics Market by Type of RNA Molecule, Therapeutic Area, Route of Administration, End User, Provisional Regions, and Sales Forecast - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.
The Canada RNA therapeutics market is projected to grow from USD 1.15 billion in the current year to USD 3.56 billion by 2035, representing a CAGR of 13.4% during the forecast period. Market expansion is being supported by advances in messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides (ASO), RNA aptamers and next generation platforms, including circular RNA (circRNA) and self-amplifying RNA (saRNA).
Canada RNA Therapeutics Market Growth and Trends
Canada holds a prominent position in the global RNA therapeutics industry, particularly in lipid nanoparticle (LNP) delivery technology. Vancouver-based Acuitas Therapeutics licensed its proprietary LNP platform for the Pfizer BioNTech COVID-19 vaccine, strengthening Canada's international role in RNA drug delivery. Precision NanoSystems, Arbutus Biopharma, Providence Therapeutics and other domestic companies further support a growing ecosystem of RNA research, platform development and commercialization.
Arbutus Biopharma is advancing LNP-formulated RNA interference candidates for chronic hepatitis B, while Calgary-based Providence Therapeutics continues to develop mRNA vaccines and therapeutic candidates. Providence Therapeutics has also announced an mRNA drug discovery partnership with the University Health Network, reinforcing collaboration between Canadian biotechnology companies and leading research institutions.
Public and private investment is accelerating the development of Canada's RNA therapeutics sector. AstraZeneca committed CAD 820 million to Canadian operations, including clinical development and job creation. Federal funding has also targeted domestic RNA manufacturing capacity to improve biomanufacturing resilience and reduce reliance on offshore production.
The market is transitioning from pandemic-driven vaccine demand toward a broader portfolio of therapies for oncological disorders, rare genetic diseases, cardiometabolic conditions and infectious diseases. Approved RNA interference products, expanding antisense oligonucleotide pipelines and next generation RNA candidates are expected to support sustained double-digit growth through 2035.
Key Canada RNA Therapeutics Market Growth Drivers
Market Challenges
The Canada RNA therapeutics market continues to face fragmented provincial reimbursement processes. Separate negotiations across Ontario, Quebec, British Columbia and other jurisdictions can delay patient access after Health Canada approval. Domestic commercial-scale manufacturing capacity also remains limited, creating reliance on international contract manufacturing organizations for late-stage clinical and commercial supply.
Cold chain requirements increase the cost and complexity of distributing certain RNA products, particularly across rural and remote communities. Smaller biotechnology companies may also experience funding gaps between early-stage research grants and capital-intensive later stage clinical trials. As a result, promising Canadian assets are sometimes licensed to larger international companies before domestic commercialization.
Canada RNA Therapeutics Market Insights
Canada RNA Therapeutics Market Segmentation
The market opportunity is analyzed by RNA molecule, therapeutic area, route of administration, end user and provincial region.
Key Segment Findings
siRNA and mRNA-based therapeutics collectively hold the largest market share, supported by approved RNA interference treatments, continued vaccine development and a growing late-stage pipeline targeting cardiometabolic and rare genetic conditions.
Ontario is expected to remain the leading provincial market through 2035 due to its concentration of academic medical centers, research hospitals and biotechnology companies. British Columbia follows, supported by Vancouver's established cluster of RNA delivery technology developers.
Oncology is forecast to record the fastest growth as clinical research expands across nucleic acid therapeutics and RNA-guided immunotherapies. Hospitals will continue to represent the largest end user segment, although subcutaneous products are creating opportunities for administration through specialty clinics and homecare settings.
Companies Active in the Canada RNA Therapeutics Market
Research Coverage
The report provides market sizing and opportunity analysis across all major segments. It assesses the Canadian RNA therapeutics landscape by molecule type, therapeutic area, development stage, administration route and company characteristics. The research also includes profiles of prominent market participants and an evaluation of initiatives undertaken by large pharmaceutical companies in Canada.
Additional coverage includes Canadian start-up health indexing, completed and ongoing clinical trials, partnerships and collaborations, funding and investment activity, and RNA therapeutics patents filed or granted through the Canadian Intellectual Property Office (CIPO). The regulatory and market access analysis examines Health Canada requirements, CADTH and INESSS assessments, provincial reimbursement, private insurance coverage and commercialization challenges.
Key Questions Addressed
Report Benefits
The report provides revenue projections, competitive intelligence and segment-level analysis for established companies, emerging biotechnology developers, investors and other stakeholders. It supports data-driven strategic planning by evaluating market demand, growth drivers, barriers, partnerships and commercialization opportunities.
Key Topics Covered:
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Canada RNA Therapeutics
6.2.1. Advantages of Canada RNA Therapeutics
6.2.2. Key Applications of Canada RNA Therapeutics
6.3. mRNA Delivery Routes
6.4. mRNA Delivery Strategies
6.5. Key Challenges Associated with Canada RNA Therapeutics
6.6. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Canada RNA Therapeutics: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Drug Candidate
7.2.3. Analysis by Type of Program
7.2.4. Analysis by Type of Delivery System
7.2.5. Analysis by Type of Molecule Encoded
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Therapeutic Area
7.3. Canada RNA Therapeutics: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Drugs Developed
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Canada RNA Therapeutics: Product Competitiveness Analysis
8.4.1. Canada RNA Therapeutics Developed by Players based in North America
8.4.2. Canada RNA Therapeutics Developed by Players based in Europe
8.4.3. Canada RNA Therapeutics Developed by Players based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES: CANADA RNA THERAPEUTICS DEVELOPERS
9.1. Chapter Overview
9.2. Leading Developers in Canada RNA Therapeutics Market based in the Region
9.2.1. Acuitas Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Canada RNA Therapeutics Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.3. Immorna
9.4. Alnylam Pharmaceuticals
9.5. Arbutus Biopharma
9.6. BioNTech
9.7. Entos Pharmaceuticals
9.8. Ionis Pharmaceuticals
9.9. Moderna
9.10. Pfizer
9.11. Precision NanoSystems
9.12. Providence Therapeutics
10. CANADIAN RNA THERAPEUTICS ECOSYSTEM AND ACADEMIC LANDSCAPE
10.1. Chapter Overview
10.2. Leading Academic and Research Institutes
10.3. RNA Therapeutics Research Centers
10.4. University-Industry Collaborations
10.5. Hospital-Based RNA Therapeutics Research
10.6. Analysis by Province
10.6.1. Ontario
10.6.2. Quebec
10.6.3. British Columbia
10.6.4. Alberta
10.6.5. Rest of Canada
10.7. Key Research and Innovation Hubs
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Big Pharma Initiatives in Canada
11.3.1. Analysis by Year of Initiative
11.3.2. Analysis by Type of Initiative
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Partnership
11.3.5. Analysis by Type of Expansion
11.3.6. Analysis by Province
11.3.7. Analysis by Company
11.4. Benchmarking Analysis of Big Pharma Players
11.5. Concluding Remarks
12. START-UP HEALTH INDEXING
12.1. Chapter Overview
12.2. Canadian Start-ups Focused on RNA Therapeutics
12.3. Benchmarking of Canadian Start-ups
12.4. Start-up Health Indexing
12.4.1. Analysis by Headquarters Location
12.4.2. Analysis by Company Strength
12.4.3. Analysis by Pipeline Maturity
12.4.4. Analysis by Pipeline Strength
12.4.5. Analysis by Financial Support
12.4.6. Analysis by Investor Strength
12.4.7. Analysis by Partnership Activity
12.4.8. Start-up Health Indexing: Roots Analysis Perspective
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Canada RNA Therapeutics: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis of Patients Enrolled by Trial Registration Year
13.3.3. Analysis by Trial Phase
13.3.4. Analysis of Patients Enrolled by Trial Phase
13.3.5. Analysis by Trial Status
13.3.6. Analysis by Trial Registration Year and Trial Status
13.3.7. Analysis by Therapeutic Area
13.3.8. Analysis by Type of RNA Molecule
13.3.9. Analysis by Study Design
13.3.9.1. Analysis by Type of Allocation
13.3.9.2. Analysis by Type of Intervention Model
13.3.9.3. Analysis by Type of Masking
13.3.9.4. Analysis by Trial Purpose
13.3.10. Analysis by Type of Sponsor / Collaborator
13.3.11. Analysis by Province
13.3.11.1. Analysis of Clinical Trials by Province
13.3.11.2. Analysis of Clinical Trials by Province and Trial Status
13.3.11.3. Analysis of Patients Enrolled by Province and Trial Status
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Canada RNA Therapeutics: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of RNA Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Most Active Players: Analysis by Number of Partnerships
14.3.7. Analysis by Province
14.3.8. Analysis by Domestic and International Partnerships
15. FUNDING AND INVESTMENTS
15.1. Chapter Overview
15.2. Funding Models
15.3. Canada RNA Therapeutics: Funding and Investment Analysis
15.3.1. Analysis by Year of Funding
15.3.1.1. Cumulative Year-wise Trend of Funding Instances
15.3.1.2. Cumulative Year-wise Trend of Amount Invested
15.3.2. Analysis by Type of Funding
15.3.2.1. Analysis of Funding Instances
15.3.2.2. Analysis of Amount Invested
15.3.3. Analysis by Year and Type of Funding
15.3.4. Analysis by Therapeutic Area
15.3.5. Analysis by Type of RNA Molecule
15.3.6. Most Active Players: Analysis by Number of Funding Instances
15.3.7. Most Active Players: Analysis by Amount Raised
15.3.8. Analysis by Province
15.3.9. Analysis by Investor Type
15.4. Summary of Funding and Investments
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Canada RNA Therapeutics: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Patent Publication Year
16.3.3. Analysis by Type of Patent and Publication Year
16.3.4. Analysis by Patent Application Year
16.3.5. Analysis by Patent Jurisdiction
16.3.6. Analysis by CPC Symbols
16.3.7. Analysis by Type of Applicant
16.3.8. Leading Industry Players: Analysis by Number of Patents
16.3.9. Leading Non-Industry Players: Analysis by Number of Patents
16.3.10. Leading Inventors: Analysis by Number of Patents
16.4. Patent Benchmarking Analysis
16.4.1. Analysis of Patent Characteristics
16.5. Patent Valuation
16.6. Leading Patents by Number of Citations
17. REGULATORY AND MARKET ACCESS ANALYSIS
17.1. Chapter Overview
17.2. Canadian Regulatory Framework for RNA Therapeutics
17.3. Health Canada Regulatory Pathways
17.3.1. New Drug Submission Pathway
17.3.2. Priority Review
17.3.3. Notice of Compliance with Conditions
17.3.4. Special Access Considerations
17.4. Clinical Development and Regulatory Requirements
17.5. Regulatory Considerations by RNA Molecule
17.6. Reimbursement and Market Access
17.6.1. CADTH Assessment
17.6.2. INESSS Assessment
17.6.3. Provincial Drug Reimbursement
17.6.4. Private Insurance Coverage
17.7. Key Regulatory and Market Access Challenges
18. OUTSOURCING: GO / NO-GO FRAMEWORK
18.1. Chapter Overview
18.2. Outsourcing: Go / No-Go Framework
18.3. Canada RNA Therapeutics Outsourcing: Go / No-Go Framework
18.3.1. Key Parameters and Assumptions
18.3.2. Methodology
18.3.3. Results and Interpretations
18.3.3.1. Outsourcing Framework for Small Companies
18.3.3.2. Outsourcing Framework for Mid-Sized Companies
18.3.3.3. Outsourcing Framework for Large Companies
18.4. Key Outsourcing Opportunities in Canada
19. MARKET IMPACT ANALYSIS
19.1. Chapter Overview
19.2. Market Drivers
19.3. Market Restraints
19.4. Market Opportunities
19.5. Market Challenges
19.6. Conclusion
20. CANADA RNA THERAPEUTICS MARKET
20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Canada RNA Therapeutics Market, Historical Trends and Forecasted Estimates
20.3.1. Historical Market Trends
20.3.2. Current Market Estimates
20.3.3. Forecasted Market Estimates
20.3.4. Conservative Scenario
20.3.5. Optimistic Scenario
20.4. Key Market Segmentations
21. CANADA RNA THERAPEUTICS MARKET, BY TYPE OF RNA MOLECULE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Canada RNA Therapeutics Market: Distribution by Type of RNA Molecule
21.3.1. Messenger RNA (mRNA), Historical Trends and Forecasted Estimates
21.3.2. Small Interfering RNA (siRNA), Historical Trends and Forecasted Estimates
21.3.3. Antisense Oligonucleotides (ASO), Historical Trends and Forecasted Estimates
21.3.4. RNA Aptamers, Historical Trends and Forecasted Estimates
21.3.5. Next Generation RNA (circRNA / saRNA), Historical Trends and Forecasted Estimates
21.4. Data Triangulation and Validation
22. CANADA RNA THERAPEUTICS MARKET, BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Canada RNA Therapeutics Market: Distribution by Therapeutic Area
22.3.1. Oncological Disorders, Historical Trends and Forecasted Estimates
22.3.2. Infectious Diseases, Historical Trends and Forecasted Estimates
22.3.3. Genetic / Rare Disorders, Historical Trends and Forecasted Estimates
22.3.4. Cardiometabolic Disorders, Historical Trends and Forecasted Estimates
22.3.5. Other Disorders, Historical Trends and Forecasted Estimates
22.4. Data Triangulation and Validation
23. CANADA RNA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Canada RNA Therapeutics Market: Distribution by Route of Administration
23.3.1. Intravenous, Historical Trends and Forecasted Estimates
23.3.2. Subcutaneous, Historical Trends and Forecasted Estimates
23.3.3. Intramuscular, Historical Trends and Forecasted Estimates
23.3.4. Other Routes, Historical Trends and Forecasted Estimates
23.4. Data Triangulation and Validation
24. CANADA RNA THERAPEUTICS MARKET, BY END USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Canada RNA Therapeutics Market: Distribution by End User
24.3.1. Hospitals, Historical Trends and Forecasted Estimates
24.3.2. Specialty Clinics, Historical Trends and Forecasted Estimates
24.3.3. Research and Academic Institutes, Historical Trends and Forecasted Estimates
24.4. Data Triangulation and Validation
25. CANADA RNA THERAPEUTICS MARKET, BY PROVINCIAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Canada RNA Therapeutics Market: Distribution by Provincial Regions
25.3.1. Ontario, Historical Trends and Forecasted Estimates
25.3.2. Quebec, Historical Trends and Forecasted Estimates
25.3.3. British Columbia, Historical Trends and Forecasted Estimates
25.3.4. Alberta, Historical Trends and Forecasted Estimates
25.3.5. Rest of Canada, Historical Trends and Forecasted Estimates
25.4. Provincial Market Dynamics Assessment
25.4.1. Penetration Growth (P-G) Matrix
25.4.2. Provincial Market Movement Analysis
25.5. Data Triangulation and Validation
26. MARKET OPPORTUNITY ANALYSIS: CANADA
26.1. Chapter Overview
26.2. Canada RNA Therapeutics Market: Opportunity Assessment by Type of RNA Molecule
26.2.1. mRNA
26.2.2. siRNA
26.2.3. ASO
26.2.4. RNA Aptamers
26.2.5. Next Generation RNA
26.3. Opportunity Assessment by Therapeutic Area
26.3.1. Oncological Disorders
26.3.2. Infectious Diseases
26.3.3. Genetic / Rare Disorders
26.3.4. Cardiometabolic Disorders
26.3.5. Other Disorders
26.4. Opportunity Assessment by Province
26.4.1. Ontario
26.4.2. Quebec
26.4.3. British Columbia
26.4.4. Alberta
26.4.5. Rest of Canada
27. MARKET OPPORTUNITY ANALYSIS: CANADIAN RNA THERAPEUTICS ECOSYSTEM
27.1. Chapter Overview
27.2. Opportunity Assessment by RNA Therapeutics Development Stage
27.3. Opportunity Assessment by Clinical Development Stage
27.4. Opportunity Assessment by Delivery Technology
27.5. Opportunity Assessment by Therapeutic Area
27.6. Opportunity Assessment by End User
27.7. Emerging Investment Opportunities
27.8. Strategic Growth Opportunities
28. CONCLUDING REMARKS
29. EXECUTIVE INSIGHTS
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/tf7htc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.